By: IPP Bureau
Last updated : September 13, 2026 6:01 am
The lens is expected to launch in additional markets during 2027 and 2028, subject to regulatory approvals and market conditions
Johnson & Johnson has received the CE Mark for its ACUVUE OASYS MAX 2-Week reusable contact lens, featuring the company’s MAX technologies, paving the way for its introduction in select European markets later this year.
The lens is expected to launch in additional markets during 2027 and 2028, subject to regulatory approvals and market conditions.
The new product is designed to address key concerns among contact lens users, including comfort and visual clarity amid increasing exposure to digital devices and blue-violet light. J&J said the lens incorporates technologies intended to support eye moisture, clarity and protection during everyday activities.
The ACUVUE OASYS MAX 2-Week features OptiBlue Light Filter, which filters at least 60% of blue-violet light, TearStable Technology to help maintain eye moisture, and Class 1 UV blocking to help protect the eyes from radiation, including sunlight.
According to the company, the technologies are designed to support visual clarity during digital device use, outdoor activities and night driving. The lens is also compatible with the existing fitting process used for ACUVUE OASYS 2-Week lenses, allowing eye-care professionals to integrate it into established fitting workflows.
Jacqueline Henderson, Group Chair, J&J MedTech Vision, said: “People who choose reusable contact lenses should not have to compromise on comfort or clarity as their days get busier and their eyes work harder.
“With ACUVUE OASYS MAX 2-Week, we are bringing our most advanced ACUVUE technologies to a reusable lens, helping more people see clearly and feel comfortable throughout the full two-week wear cycle.”
The product forms part of the ACUVUE OASYS MAX portfolio, which offers advanced options for reusable contact lens users.
The development follows J&J’s recent regulatory progress in other medical technology segments. In July, the company received US Food and Drug Administration approval for its Dual Energy Thermocool Smarttouch SF Platform.